european end-to-end CDMO company, pharma services
  • About us
    • History
    • Leaderships
    • Team
    • EU grants
    • Requests for Proposal
    • Sustainability – ESG
    • Bussines strategy
    • Quality policy
    • Virtual Tour
  • Services
    • Drug Substance Manufacturing
    • Fill & Finish
    • Gene to Vial: End-to-End Development
    • Process Development
    • Analytics 
    • Cell Line Development & Banking
  • Science Hub
    • Science News
    • Resources
  • News & Events
    • Press releases
    • Events
    • Content to download
  • Investors
    • Corporate documents
    • Shareholders and shares
    • Periodic reports
    • Current reports
    • Sustainability reports
    • Corporate governance at Mabion
    • Financial data
    • For Investors
    • Calendar
  • Contact us
    • Contact form
    • Contact for investors
    • Contact for media
    • Careers
  • EN
  • Science News
  • Resources

Biologics

Biologics CDMO

Biologics CDMO Solutions for the Future of Therapeutics

Biologics, Drug development, Manufacturing
Validation strategy for B-cell flow cytometry

Bioanalytical Assay Strategies and Considerations for Validation of B Cells-Depletion Assay by Flow Cytometry

Bioanalytics, Biologics
Biologics drugs to be approved in 2024.

Top 5 most expected biologics in 2024

Biologics, Drug development, EMA, FDA, Regulatory
EMA and FDA

Similar but not the same: an in-depth look at the differences between EMA and FDA

Biologics, EMA, FDA, Regulatory
FDA approved biologics in 2023

Top 10 biologics approved in 2023

Biologics, EMA, FDA, Monoclonal antibody, Vaccines
Veterinary Monoclonal Antibodies

Development and regulation of veterinary monoclonals

Biologics, Drug development, Regulatory, Veterinary biologics
Immunogenicity Impact on Efficacy and Safety of Biosimilars

Impact of immunogenicity on efficacy and safety of biosimilars – importance of ADA and nAb testing during the clinical development

Biologics, Drug product
Mycoplasma Contamination Risks in Biomanufacturing

Mycoplasma contamination in biopharmaceutical manufacturing

Biologics, Cell culture, Contamination, Manufacturing
Glycosylation's Impact on Antibody Effector Functions

Impact of glycosylation on the effector functions of monoclonal antibodies: a case study of rituximab

Bioanalytics, Biologics, Drug substance, Manufacturing
Previous 1 2 3

Contact

Find out how we may support your business.

bd@mabion.eu

Mabion

gen. Mariana Langiewicza 60
95-050 Konstantynów Łódzki
Poland

+48 42 207 78 90

    Mabion
    • Privacy policy
    • Services
    • Investors
    • News&Events
    • Contact us

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Page Sitemap.

    Powered by

    Veneo